Lyell
is a California-based clinical-stage biotechnology company that develops novel T-cell therapies for the treatment of cancer... Read moreLyell
is a California-based clinical-stage biotechnology company that develops novel T-cell therapies for the treatment of cancer... Read more
News
Jun 12, 2026
GlobeNewswire
Press Release: Lyell : Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
Jun 08, 2026
Benzinga
Lyell: Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update
Jun 05, 2026
GlobeNewswire
Press Release: Lyell : Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
Jun 01, 2026
GlobeNewswire
Press Release: Lyell : Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
May 12, 2026
GlobeNewswire
Press Release: Lyell : Lyell Immunopharma Announces Participation in May Investor Conferences
May 07, 2026
Owler
Lyell Immunopharma, Inc.: Lyell's revenue changed from $36K in Dec 2025 to $31K in Mar 2026
May 07, 2026
GlobeNewswire
Press Release: Lyell : Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
May 07, 2026
RTTNews
Lyell: Lyell Records $24 Mln Loss In Q1, Provides Updates On CAR-T Cell Therapies For Cancer Treatment
Apr 17, 2026
Seeking Alpha
Lyell: Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Mar 13, 2026
Owler
Lyell Immunopharma, Inc.: Lyell's employee count changed from 300 in Dec 2024 to 161 in Dec 2025
Lyell Competitors
1
2
3
4
5
6
7
8
9
10